ATE315934T1 - Thrombopoietin-mimetika - Google Patents

Thrombopoietin-mimetika

Info

Publication number
ATE315934T1
ATE315934T1 AT00961674T AT00961674T ATE315934T1 AT E315934 T1 ATE315934 T1 AT E315934T1 AT 00961674 T AT00961674 T AT 00961674T AT 00961674 T AT00961674 T AT 00961674T AT E315934 T1 ATE315934 T1 AT E315934T1
Authority
AT
Austria
Prior art keywords
mammal
invented
thrombopoietin mimetics
mimetics
thrombopoietin
Prior art date
Application number
AT00961674T
Other languages
English (en)
Inventor
Juan I Luengo
Kevin J Duffy
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Application granted granted Critical
Publication of ATE315934T1 publication Critical patent/ATE315934T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
    • C07D231/46—Oxygen atom in position 3 or 5 and nitrogen atom in position 4
    • C07D231/48—Oxygen atom in position 3 or 5 and nitrogen atom in position 4 with hydrocarbon radicals attached to said nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00961674T 1999-09-10 2000-09-08 Thrombopoietin-mimetika ATE315934T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15335899P 1999-09-10 1999-09-10
US20366800P 2000-05-12 2000-05-12

Publications (1)

Publication Number Publication Date
ATE315934T1 true ATE315934T1 (de) 2006-02-15

Family

ID=26850465

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00961674T ATE315934T1 (de) 1999-09-10 2000-09-08 Thrombopoietin-mimetika

Country Status (7)

Country Link
EP (1) EP1213965B1 (de)
JP (1) JP4488663B2 (de)
AT (1) ATE315934T1 (de)
AU (1) AU770564B2 (de)
DE (1) DE60025632T2 (de)
ES (1) ES2256038T3 (de)
WO (1) WO2001017349A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CY2010012I2 (el) 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
JP3966816B2 (ja) 2000-05-30 2007-08-29 中外製薬株式会社 トロンボポエチン様活性を有する化合物
EP1370252A4 (de) * 2001-03-01 2006-04-05 Smithkline Beecham Corp Thrombopoietin-mimetika
AR040083A1 (es) 2002-05-22 2005-03-16 Smithkline Beecham Corp Compuesto bis-(monoetanolamina) del acido 3'-[(2z)-[1-(3,4-dimetilfenil) -1,5-dihidro-3-metil-5-oxo-4h-pirazol-4-iliden] hidrazino] -2'-hidroxi-[1,1'-bifenil]-3-carboxilico, procedimiento para prepararlo, composicion farmaceutica que lo comprende, procedimiento para preparar dicha composicion farmac
WO2004016264A1 (ja) 2002-08-14 2004-02-26 Nissan Chemical Industries, Ltd. トロンボポエチンレセプター活性化剤ならびにそれらの製造方法
TWI324593B (en) 2002-10-09 2010-05-11 Nissan Chemical Ind Ltd Pyrazolone compounds and thrombopoietin receptor activator
TW200526638A (en) 2003-10-22 2005-08-16 Smithkline Beecham Corp 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline
WO2005118551A2 (en) 2004-05-28 2005-12-15 Ligand Pharmaceuticals Inc. Thrombopoietin activity modulating compounds and methods
CA2583764C (en) 2004-10-25 2009-06-09 Ligand Pharmaceuticals, Inc. Thrombopoietin activity modulating compounds and methods
CA2588979C (en) 2004-12-08 2013-01-22 Nissan Chemical Industries, Ltd. 3-ethylidenehydrazino substituted heterocyclic compounds as thrombopoietin receptor activators
WO2006064957A1 (ja) 2004-12-14 2006-06-22 Nissan Chemical Industries, Ltd. アミド化合物及びトロンボポエチンレセプター活性化剤
WO2007010954A1 (en) 2005-07-15 2007-01-25 Nissan Chemical Industries, Ltd. Thiophene compounds and thrombopoietin receptor activators
WO2007011056A1 (en) 2005-07-20 2007-01-25 Nissan Chemical Industries, Ltd. Pyrazole compounds and thrombopoietin receptor activators
WO2007020426A1 (en) * 2005-08-19 2007-02-22 Astrazeneca Ab Pyrazolone derivatives for the treatment of tuberculosis
EP1947101A4 (de) 2005-11-07 2009-09-16 Nissan Chemical Ind Ltd Hydrazidverbindung und thrombopoietinrezeptoraktivator
BRPI0620532A2 (pt) * 2005-11-23 2011-11-16 Ligand Pharm Inc compostos e métodos para modular a atividade de trombopoietina
JP5157900B2 (ja) 2006-06-07 2013-03-06 日産化学工業株式会社 含窒素ヘテロ環化合物及びトロンボポエチンレセプター活性化剤
EP2086551A4 (de) * 2006-12-01 2011-06-08 Stategics Inc Thrombopoietin-mimetika
ECSP077628A (es) 2007-05-03 2008-12-30 Smithkline Beechman Corp Nueva composición farmacéutica
CN101481352A (zh) 2008-01-10 2009-07-15 上海恒瑞医药有限公司 双环取代吡唑酮偶氮类衍生物、其制备方法及其在医药上的应用
PE20100362A1 (es) 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
CA2763768A1 (en) 2009-05-29 2010-12-02 Glaxosmithkline Llc Methods of administration of thrombopoietin agonist compounds
CN101921232A (zh) 2009-06-11 2010-12-22 上海恒瑞医药有限公司 双环取代吡唑酮偶氮类衍生物的盐,其制备方法及其在医药上的应用
WO2012102937A2 (en) 2011-01-25 2012-08-02 Irm Llc Compounds that expand hematopoietic stem cells
US9834755B2 (en) 2011-12-08 2017-12-05 Fred Hutchinson Cancer Research Center Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
PL2807165T3 (pl) 2012-01-27 2019-09-30 Université de Montréal Pochodne pirymido[4,5-b]indolu i ich zastosowanie do namnażania hematopoetycznych komórek macierzystych
CN103232730B (zh) * 2013-01-10 2015-01-14 浙江山峪染料化工有限公司 一种混拼型分散黄染料
CN103232727B (zh) * 2013-01-10 2014-09-03 浙江山峪染料化工有限公司 一种多组份拼混型分散黄染料
CN103232728B (zh) * 2013-01-10 2014-08-20 浙江山峪染料化工有限公司 混拼型分散黄染料
CN103232729A (zh) * 2013-01-10 2013-08-07 浙江山峪染料化工有限公司 多组份拼混型分散黄染料配方
CN103044968B (zh) * 2013-01-11 2014-10-22 浙江山峪染料化工有限公司 一种分散黄染料
US10647718B2 (en) 2014-04-22 2020-05-12 Universitéde Montréal Compounds and use thereof in the expansion of hematopoietic stem cells and/or hematopoietic progenitor cells
TW201615228A (zh) 2014-10-31 2016-05-01 Nissan Chemical Ind Ltd 配體結合纖維及使用該纖維之細胞培養基材
EP3886854A4 (de) 2018-11-30 2022-07-06 Nuvation Bio Inc. Pyrrol- und pyrazolverbindungen und verfahren zu deren verwendung

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5482546A (en) * 1994-03-30 1996-01-09 Canon Kabushiki Kaisha Dye, ink containing the same, and ink-jet recording method and instrument using the ink
GC0000177A (en) * 1998-12-17 2006-03-29 Smithkline Beecham Thrombopoietin mimetics

Also Published As

Publication number Publication date
DE60025632D1 (de) 2006-04-06
AU770564B2 (en) 2004-02-26
EP1213965B1 (de) 2006-01-18
WO2001017349A1 (en) 2001-03-15
JP2003508463A (ja) 2003-03-04
ES2256038T3 (es) 2006-07-16
AU7359400A (en) 2001-04-10
EP1213965A1 (de) 2002-06-19
DE60025632T2 (de) 2006-08-10
EP1213965A4 (de) 2003-05-02
JP4488663B2 (ja) 2010-06-23

Similar Documents

Publication Publication Date Title
ATE350044T1 (de) Thrombopoietinmimetika
ATE315934T1 (de) Thrombopoietin-mimetika
ATE344031T1 (de) Thrombopoietin-mimetika
MY136707A (en) Thrombopoietin mimetics
WO2002049413A3 (en) Thrombopoietin mimetics
HK1043472A1 (zh) 血小板减少症拟态
WO2004054515A3 (en) Thrombopoietin mimetics
EP1133291A4 (de) Verfahren zur behandlung der thrombozytopenie
CY1108221T1 (el) Μεθοδος για την αναπαραγωγη πλευρομουτιλινων
DE60124684D1 (de) Sulfonamido-substituierte verbrückte bicycloalkylderivative
DE60101265D1 (de) Behandlung von augenschmerzen
EP1610778A4 (de) Behandlung von benigner prostatahyperplasie
ATE203519T1 (de) Chinolinderivate als antimalariamittel
ATE516027T1 (de) Orazamid orotat zur vorbeugung von leberschäden
EP1117431A4 (de) Behandlung von acidose
EP1441761A4 (de) Verfahren zur prävention und behandlung von infektionen mit dem flavivirus bei tieren
DK1305037T3 (da) Smertestillende medikament
EP1315503A4 (de) Behandlung von harnstörungen
DE60103685D1 (de) Behandlung von Poriomania
DE60110748D1 (de) Behandlung von fluorkohlenstoff-beschickungen
CY1106363T1 (el) Χρηση του ενepγοποιημενου παραγοντα πηξης vii για την αγωγη των επαγομενων απο θρομβολυτικη θepαπεια μειζονων αιμορραγιων
ATE302008T1 (de) Behandlung von entzündlichen erkrankungen
EA200100785A1 (ru) Шипучие слабительные средства
LU91009B1 (de) Behandlung von Verbrennungen
ATE294590T1 (de) Verwendung von interleukin-11 zur behandlung von hämoragischem schock

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties